Moderna (MRNA) Long-Term Investments (2017 - 2026)
Moderna (MRNA) posted quarterly Long-Term Investments of $1.8 billion for Q2 2026, down 25.36% year-over-year from $2.4 billion in Q2 2025, and down 21.28% on a QoQ basis from $2.3 billion in Q1 2026.
Moderna (MRNA) Long-Term Investments (2017 - 2026) Analysis & Trends
Moderna has reported Long-Term Investments for 10 years, with the latest figure at $1.8 billion in Q2 2026.
- Long-Term Investments for Q2 2026 came in at $1.8 billion, down 25.36% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.8 billion (down 25.36% YoY), and the FY2025 annual result was $2.3 billion, down 6.34% from the prior year.
- Long-Term Investments slipped to $1.8 billion in Q2 2026, from $2.3 billion in the prior quarter.
- Over five years, Long-Term Investments peaked at $10.2 billion in Q2 2022 and troughed at $36.0 million in Q1 2023.
- A 5-year average of $4.2 billion and a median of $2.5 billion in 2024 frame the typical range for Long-Term Investments.
- The widest annual swing landed in 2023, when Long-Term Investments tumbled 99.61%; it then jumped 10005.56% in 2024.
- A 5-year view of Long-Term Investments shows it stood at $8.3 billion in 2022, then slumped by 43.77% to $4.7 billion in 2023, then tumbled by 46.68% to $2.5 billion in 2024, then retreated by 6.34% to $2.3 billion in 2025, then dropped by 24.14% to $1.8 billion in 2026.
- Per Business Quant data, the three most recent Long-Term Investments figures were $1.8 billion in Q2 2026, $2.3 billion in Q1 2026, and $2.3 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Moderna | 25.26 Bn | 20.13 Bn | 52.00 Mn | 1.77 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.77 Bn |
| Mar 31, 2026 | 2.25 Bn |
| Dec 31, 2025 | 2.34 Bn |
| Sep 30, 2025 | 2.14 Bn |
| Jun 30, 2025 | 2.37 Bn |
| Mar 31, 2025 | 2.42 Bn |
| Dec 31, 2024 | 2.49 Bn |
| Sep 30, 2024 | 2.34 Bn |
| Jun 30, 2024 | 2.33 Bn |
| Mar 31, 2024 | 3.64 Bn |
| Dec 31, 2023 | 4.68 Bn |
| Sep 30, 2023 | 5.27 Bn |
| Jun 30, 2023 | 6.11 Bn |
| Mar 31, 2023 | 36.00 Mn |
| Dec 31, 2022 | 8.32 Bn |
| Sep 30, 2022 | 8.66 Bn |
| Jun 30, 2022 | 10.16 Bn |
| Mar 31, 2022 | 9.17 Bn |
| Dec 31, 2021 | 6.84 Bn |
| Sep 30, 2021 | 6.44 Bn |